Company intelligence / Profile preview

Sygnature Chemical Services

Nottingham, Nottinghamshire, United Kingdom

Ownership: Private
Employees: ~1000
Development stage: Other

Overview

Since 2011, Sygnature Discovery has delivered 56+ novel pre-clinical and 35+ clinical compounds, with scientists named on over 235 patents[2][3]. The company has delivered 12 clinical candidates in oncology (spanning Phase 1-3 trials) and serves as a service provider rather than a drug developer[6].

Modalities: Small moleculeMonoclonal antibodyAntibody-drug conjugateRNA/DNA therapeuticsViral and cell therapiesRadiotherapy
Industry: Drug Discovery Services

Beyond the preview

Go deeper on Sygnature Chemical Services.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sygnature Chemical Services.

Explore the full profile